Member access

4-Traders Homepage  >  Shares  >  Nyse MKT  >  IGI LABORIGI       

 SummaryChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Company
IGI Laboratories, Inc. develops, manufactures and markets topical formulations.The company sells generic topical pharmaceutical products under IGI label.It also provides development, formulation, and manufacturing services to the pharmaceutical, over-the-counter and cosmetic markets.The company's... 
Sector
Pharmaceuticals
Calendar
03/17Earnings Release
More about the company
Surperformance© ratings of IGI LABORIGI
Trading Rating : Investor Rating : -
More Ratings
Chart IGI LABORIGI
Duration : Period :
IGI LABORIGI Technical Analysis Chart | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 31,9 M
EBIT 2014 2,80 M
Net income 2014 2,58 M
Debt 2014 -
Yield 2014 -
Sales 2015 60,4 M
EBIT 2015 15,3 M
Net income 2015 14,1 M
Debt 2015 -
Yield 2015 -
PER 2014 199,20
PER 2015 37,94
Capi. / Sales 2014 16,5x
Capi. / Sales 2015 8,71x
Capitalization 526 M
More Financials
Latest news on IGI LABORIGI
01/26 Questions raised over Swiss franc retail trades
01/08 IGI LABORATORIES : To Present At 33rd Annual J.P. Morgan Healthcare Conference O..
2014 IGI LABORATORIES : Announces Three Additional ANDA Submissions
2014 IGI LABORATORIES : Announces Closing of Initial Purchasers' Exercise in Full of ..
2014 IGI LABORATORIES : Consumer Staples Industry Equities under the Scanner -- Proct..
2014 IGI LABORATORIES : Announces Closing of $125 Million of 3.75% Convertible Senior..
2014 IGI LABORATORIES : Announces Pricing of $125 Million of 3.75% Convertible Senior..
2014 IGI LABORATORIES : To Present At 25TH Annual Oppenheimer Healthcare Conference O..
More news
Sector news Pharmaceuticals - NEC
09:15a JOHNSON & JOHNSON : Former FDA chief calls J&J misleading on Risperdal
01/30 SANOFI : 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana..
01/30 ABBVIE : breakup with Shire torpedoes 4th quarter, 2014 results
Plus d'actualités du secteur Pharmaceuticals - NEC
Comments 
Advertisement
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF